193 related articles for article (PubMed ID: 25866336)
1. Cytomegalovirus appendicitis in solid organ transplant patients, two cases and a review.
McCarty TP; Lee RA; Herfel BM; Pappas PG
J Clin Virol; 2015 May; 66():48-50. PubMed ID: 25866336
[TBL] [Abstract][Full Text] [Related]
2. Subacute cytomegalovirus appendicitis in a renal transplant recipient.
Posen A; Renckens I; Sagaert X; Kuypers D
Transpl Infect Dis; 2013 Feb; 15(1):96-7. PubMed ID: 23075276
[TBL] [Abstract][Full Text] [Related]
3. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
4. Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients.
Razonable RR
Infect Dis Clin North Am; 2013 Jun; 27(2):317-42. PubMed ID: 23714343
[TBL] [Abstract][Full Text] [Related]
5. Small bowel transplantation complicated by cytomegalovirus tissue invasive disease without viremia.
Avsar Y; Cicinnati VR; Kabar I; Wolters H; Anthoni C; Schmidt HH; Beckebaum S
J Clin Virol; 2014 Jun; 60(2):177-80. PubMed ID: 24703746
[TBL] [Abstract][Full Text] [Related]
6. Ganciclovir-Resistant Cytomegalovirus Infection in Abdominal Solid Organ Transplant Recipients: Case Series and Review of the Literature.
Rolling KE; Jorgenson MR; Descourouez JL; Mandelbrot DA; Redfield RR; Smith JA
Pharmacotherapy; 2017 Oct; 37(10):1258-1271. PubMed ID: 28699311
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.
Boivin G; Goyette N; Rollag H; Jardine AG; Pescovitz MD; Asberg A; Ives J; Hartmann A; Humar A
Antivir Ther; 2009; 14(5):697-704. PubMed ID: 19704173
[TBL] [Abstract][Full Text] [Related]
8. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients.
Humar A; Siegal D; Moussa G; Kumar D
J Infect Dis; 2005 Oct; 192(7):1154-7. PubMed ID: 16136456
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients.
Boivin G; Goyette N; Gilbert C; Humar A; Covington E
Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409
[TBL] [Abstract][Full Text] [Related]
10. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
Cervera C; Pineda M; Linares L; Marcos MA; Esteva C; Antón A; Cofán F; Ricart MJ; Navasa M; Pérez-Villa F; Pumarola T; Moreno A
Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients.
Luan FL; Chopra P; Park J; Norman S; Cibrik D; Ojo A
Transplant Proc; 2006 Dec; 38(10):3673-5. PubMed ID: 17175363
[TBL] [Abstract][Full Text] [Related]
12. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
Torres-Madriz G; Boucher HW
Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.
Razonable RR; Humar A
Clin Transplant; 2019 Sep; 33(9):e13512. PubMed ID: 30817026
[TBL] [Abstract][Full Text] [Related]
14. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.
Martin M; Goyette N; Ives J; Boivin G
J Clin Virol; 2010 Apr; 47(4):321-4. PubMed ID: 20138805
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests.
Fica A; Cervera C; Pérez N; Marcos MA; Ramírez J; Linares L; Soto G; Navasa M; Cofan F; Ricart MJ; Pérez-Villa F; Pumarola T; Moreno A
Transpl Infect Dis; 2007 Sep; 9(3):203-10. PubMed ID: 17511827
[TBL] [Abstract][Full Text] [Related]
16. Prevention of cytomegalovirus disease using pre-emptive treatment after solid organ transplant in patients at high risk for cytomegalovirus infection.
Benmarzouk-Hidalgo OJ; Cordero E; Martín-Peña A; García-Prado E; Gentil MA; Gomez-Bravo MA; Barrera-Pulido L; Cisneros JM; Perez-Romero P
Antivir Ther; 2009; 14(5):641-7. PubMed ID: 19704166
[TBL] [Abstract][Full Text] [Related]
17. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis.
Boivin G; Goyette N; Gilbert C; Covington E
J Med Virol; 2005 Nov; 77(3):425-9. PubMed ID: 16173018
[TBL] [Abstract][Full Text] [Related]
18. Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.
Asberg A; Rollag H; Hartmann A
Expert Opin Pharmacother; 2010 May; 11(7):1159-66. PubMed ID: 20367273
[TBL] [Abstract][Full Text] [Related]
19. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir.
Fellay J; Venetz JP; Aubert JD; Seydoux C; Pascual M; Meylan PR
Transplant Proc; 2005 Mar; 37(2):949-51. PubMed ID: 15848585
[TBL] [Abstract][Full Text] [Related]
20. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
